Welcome to our dedicated page for ENvue Medical SEC filings (Ticker: FEED), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page is intended to provide access to ENvue Medical, Inc. (NASDAQ: FEED) regulatory filings once they are available through the SEC’s EDGAR system. ENvue describes itself as a medical technology company focused on non-invasive and minimally invasive solutions, including the ENvue Navigation Platform for feeding-tube placement and acoustic-based therapeutic devices such as PainShield and UroShield.
For a company with these activities, investors typically look to annual reports on Form 10-K and quarterly reports on Form 10-Q for detailed information on technology platforms, risk factors related to medical devices, research and development efforts, and the regulatory environment for enteral care and acoustic-based therapies. Current reports on Form 8-K can describe material events such as product launches, strategic programs, or significant corporate changes.
When insider transaction reports on Form 4 are filed, they can show purchases or sales of ENvue equity by directors, officers, or other insiders, which some investors review alongside the company’s technology and commercialization updates. Proxy statements on Schedule 14A, when filed, may provide information on governance, board composition, and executive compensation in the context of ENvue’s medical technology focus.
On Stock Titan, ENvue Medical filings are paired with AI-powered summaries designed to explain the main points of lengthy documents, highlight key sections, and make complex regulatory language easier to understand. As new ENvue filings are released on EDGAR, this page updates so users can quickly review the latest 10-K, 10-Q, 8-K, and Form 4 disclosures along with plain-language AI insights.
ENvue Medical, Inc. reports an amended Schedule 13G showing 0.0% ownership by Bank of America Corporation. The filing states 14 shares beneficially owned with 14 shares of shared voting and dispositive power. The beneficial ownership calculation cites December 5, 2025 outstanding share totals of 1,088,192 from a Form 424B3 prospectus.
ENvue Medical, Inc. reported that Nicole M. Fernandez-McGovern, the company’s Interim CFO, filed an initial statement of beneficial ownership on Form 3. This filing establishes her official insider status and discloses her equity position in the company as required for officers under SEC rules.
Envue Medical, Inc. insider Christian Michael Glibert, a more than 10% owner, reports beneficial ownership of 240,000 shares of common stock held directly as of January 14, 2026. The company states there were 1,088,192 shares of common stock outstanding as of February 2026; this is a baseline figure, not the amount reported as owned.
ENvue Medical 10% owner Christian Michael Glibert bought 240,000 common shares in the open market. The purchase on January 14, 2026 was at a weighted average price of $2.67 per share, with individual trades ranging from $2.47 to $2.90.
Following this transaction, Glibert directly owns 240,000 shares of ENvue Medical common stock. A footnote states that the ownership percentage is calculated against 1,088,192 shares of common stock outstanding as of the issuer’s most recent February 2026 filings, indicating this is a meaningful stake.
ENvue Medical, Inc. shareholder Christian Michael Glibert filed a Schedule 13D disclosing beneficial ownership of 240,000 shares of common stock, representing about 22.05% of the company based on 1,088,192 shares outstanding as of February 2026. On January 14, 2026, he purchased 240,000 shares in an open market transaction at an average price of $2.67 per share, using personal funds totaling approximately $640,737.85. He states the shares were acquired for investment purposes and that he may buy more or sell some in the future, but reports no current plans for corporate actions and no contracts or arrangements with others regarding the issuer’s securities.
Bank of America Corporation filed a Schedule 13G reporting beneficial ownership of 234,235 shares of ENvue Medical common stock, representing 21.5% of the outstanding class.
The filing shows Bank of America, through BofA Securities, Inc. and Bank of America N.A., has shared voting and dispositive power over these shares and certifies the position is held in the ordinary course of business without the purpose of influencing control. The disclosure notes that the ownership percentage is based on 1,088,192 outstanding shares from a recent ENvue prospectus, which also describes a potential resale of up to 7,962,279 additional shares that could significantly increase outstanding shares and dilute existing holders.
ENvue Medical, Inc. reported changes to leadership compensation and governance. A subsidiary signed a first amendment to the employment agreement with CEO Doron Besser, M.D., confirming an initial grant of 180,000 restricted stock units, equal to 9% of the company’s fully diluted common stock as of his agreement’s effective date.
The amendment also provides quarterly restricted stock unit “gross-up” grants, subject to board approval, to keep Dr. Besser at a 9% equity interest, including a prorated grant if he is terminated without Cause or resigns for Good Reason. Separately, ENvue entered a chairman agreement with David Johnson, who will chair the board as an independent contractor, receive a flat $10,000 monthly fee, and be granted restricted stock units representing 3.5% of fully diluted common stock, plus potential anti-dilution true-up grants for up to two years.
Bank of America and affiliates filed an amended Form 3/A for ENvue Medical, Inc., updating the reported event date to January 30, 2026 and confirming 10% owner status. The filing reports indirect beneficial ownership of 234,056 shares of common stock through subsidiaries BANA and BOFAS.
The disclosure relies on 1,088,192 outstanding shares as of December 5, 2025, as stated in a December 18, 2025 prospectus, which covers the resale of up to 7,962,279 shares of common stock and notes that additional issuances could materially increase outstanding shares and substantially dilute existing stockholders.
Bank of America Corp, BOFA Securities and Bank of America NA jointly reported a series of open-market sales of ENvue Medical, Inc. (FEED) common stock on 02/02/2026. The trades were executed at prices generally around $3.04–$3.07 per share, each reducing the reported indirect position.
After these transactions, the reporting persons show 231,138 shares of ENvue Medical common stock beneficially owned on an indirect basis. The footnotes explain that Bank of America’s interest is indirect through its subsidiaries and include disclaimers about group status and greater-than-10% beneficial ownership.